Article
An orally bioavailable tyrosine kinase inhibitor demonstrated dramatic and rapid effects on advanced prostate cancer, according to researchers from the University of Michigan Comprehensive Cancer Center, Ann Arbor.
Subcutaneous nivolumab approved in EU, Canada for solid tumors
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
Application submitted to FDA for 510(k) clearance of Men’s Sexual Health Test
Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
Clarifying CPT 52353 billing for same-side stone cases
Expert discusses the promise of emerging MISTs for BPH
Phase 3 trial of tebipenem HBr for cUTI stopped early for efficacy
Combination therapy linked to longer OS vs ADT in veterans with mHSPC